Statistics from Altmetric.com
Idiopathic pulmonary fibrosis (IPF) is a rare disease with a very debilitating course for which only limited therapeutic options are available. The incidence of IPF is increasing worldwide and in Italy ranges between 7.5 and 9.3 new cases per 100 000 per year.1 It is characterized by progressive and irreversible scarring of lung tissue resulting in a decline in respiratory function and usually a fatal outcome; survival of patients with IPF is usually less than 5 years from diagnosis.2 Currently, pharmacological treatments include only two active ingredients to delay disease progression: nintedanib, a tyrosine kinase inhibitor, and pirfenidone, a molecule with anti-inflammatory and antifibrotic activities. A retrospective analysis was conducted by hospital pharmacy staff at a …
Contributors Conceptualization: LM and AZ. Methodology: LM and CB. Investigation: LM and CB. Writing original draft: LM and AZ. Review and editing: AZ. Visualisation: CB and AZ.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.